<DOC>
	<DOCNO>NCT01159496</DOCNO>
	<brief_summary>This multiple ascend dose study assess safety , tolerability pharmacokinetics PF-05212377 ( SAM-760 ) administer orally day 14 day healthy young adult healthy elderly subject . The study conduct double-blind condition ( neither investigator subject know he/she receive PF-05212377 placebo ) . The Sponsor know subject receive active treatment placebo .</brief_summary>
	<brief_title>Multiple Ascending Dose Study To Assess Safety , Tolerability And Pharmacokinetics Of PF-05212377 ( SAM-760 )</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria young healthy population : Healthy male and/or female subject nonchild bear potential ( WONCBP ) age 18 55 year , inclusive . ( Healthy define clinically relevant abnormality identify screen detailed medical history , full physical examination , include blood pressure heart rate measurement , 12lead ECG , neurological examination clinical laboratory test . ) Inclusion Criteria elderly population : Healthy male and/or female subject nonchild bear potential age 65 85 year , inclusive . Subjects must reasonably good health determine investigator base detailed medical history , full physical examination ( include blood pressure pulse rate measurement ) , 12lead ECG clinical laboratory test . Subjects mild , chronic , stable disease ( eg , control hypertension , noninsulin dependent diabetes , osteoarthritis ) may enrol deem medically prudent investigator . Presence history disorder may prevent successful completion study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . A score great equal 20 Beck Depression Inventory and/or response 1 , 2 , 3 question relate suicide . History seizure disorder and/or severe head trauma ( single childhood febrile seizure ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , dermatologic , muscular allergic disease disorder ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any surgical medical condition may interfere absorption , distribution , metabolism , excretion study treatment . Acute disease state ( eg , nausea , vomit , fever , diarrhea ) within 7 day study Day 1 . History drug abuse within 1 year study Day 1 positive urine drug screen . Admitted alcohol abuse history alcohol use may interfere subject 's ability comply protocol requirement . Consumption 14 drinks/week female 21 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Subjects smoke 10 cigarette per day . Pregnant nursing female ; female childbearing potential . Males unwilling abstain sexual intercourse use condom childbearing potential woman duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>